

IMMUNOBIOLOGICS

IMMUNOBIOLOGIC	PRIMARY IMMUNIZATION SCHEDULE	BOOSTER SCHEDULE	COMMENTS AND CONTRAINDICATIONS														
<p>Pneumococcal Conjugate Vaccine (PCV)</p> <p>Prevnar™ Wyeth</p>	<p>The number of doses recommended depends on the age of the infant or child when beginning the series:</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 30%;">Age at first dose:</td> <td>Schedule (Dose 0.5 mL IM)</td> </tr> <tr> <td>2*-6 months</td> <td>3 doses, 2 months apart[§]</td> </tr> <tr> <td>7-11 months</td> <td>2 doses, 2 months apart[§]</td> </tr> <tr> <td>12-23 months</td> <td>2 doses 2 months apart[†]</td> </tr> <tr> <td>24-59 months</td> <td></td> </tr> <tr> <td> Healthy children</td> <td>1 dose</td> </tr> <tr> <td> High-risk children</td> <td>2 doses, 2 months apart[†] (See comments)</td> </tr> </table> <p>* Minimum age is 6 weeks of age [§] For children vaccinated at age < 1 year, minimum interval between doses is 4 weeks [†] Minimum interval between doses is 8 weeks</p>	Age at first dose:	Schedule (Dose 0.5 mL IM)	2*-6 months	3 doses, 2 months apart [§]	7-11 months	2 doses, 2 months apart [§]	12-23 months	2 doses 2 months apart [†]	24-59 months		Healthy children	1 dose	High-risk children	2 doses, 2 months apart [†] (See comments)	<p>Additional Dose: (Dose: 0.5 mL IM)</p> <p>1 dose at 12-15 months[†] 1 dose at 12-15 months[†] none</p> <p>none none</p> <p>[†] At least 8 weeks after last dose</p>	<p>Pneumococcal conjugate vaccine (PCV) is recommended for:</p> <ul style="list-style-type: none"> • All children younger than 24 months • All healthy children aged 24--59 months who have not completed any recommended schedule for PCV7, administer 1 dose of PCV7 • Unimmunized children aged 24-59 months with one of the following underlying medical condition, administer 2 doses of PCV7*: <ul style="list-style-type: none"> ○ sickle cell disease and other sickle cell hemoglobinopathies, congenital or acquired asplenia, or splenic dysfunction ○ infection with human immunodeficiency virus (HIV) ○ immunocompromising conditions, including congenital immunodeficiencies (B-lymphocyte [humoral] or T-lymphocyte deficiency); complement deficiencies, particularly c1, c2, c3, and c4 deficiency; and phagocytic disorders, (excluding chronic granulomatous disease); renal failure and nephritic syndrome; diseases associated with immunosuppressive therapy or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin's disease, or solid organ transplantation ○ chronic illnesses, including chronic cardiac disease, particularly cyanotic congenital heart disease and cardiac failure; chronic pulmonary disease (excluding asthma unless on high-dose corticosteroid therapy); cerebrospinal fluid leaks; diabetes mellitus; cochlear implant recipients <p>* If a child with underlying medical conditions aged 24-59 months has received 3 doses previously, administer 1 dose; if a child with underlying medical conditions aged 24-59 months has received < 3doses previously, administer 2 doses of PCV7 at least 8 weeks apart.</p> <p>Adverse Reactions: Injection site redness and/or soreness. Local reactions are more common with the fourth dose than with the first three doses. No severe adverse events attributable to PCV7 have been reported.</p> <p>Contraindications: History of a serious allergic reaction to a prior dose of PCV or to a vaccine component, including diphtheria toxoid. Acute moderate to severe illness until illness improved.</p>
Age at first dose:	Schedule (Dose 0.5 mL IM)																
2*-6 months	3 doses, 2 months apart [§]																
7-11 months	2 doses, 2 months apart [§]																
12-23 months	2 doses 2 months apart [†]																
24-59 months																	
Healthy children	1 dose																
High-risk children	2 doses, 2 months apart [†] (See comments)																